EmailFacebookXLinkedIn

Lina_S

About Lina Silva Salinas

This author has not yet filled in any details.
So far Lina Silva Salinas has created 418 blog entries.

Adherence to oral cancer therapy in older adults: The International Society of Geriatric Oncology (SIOG) taskforce recommendations

2021-08-05T08:16:48+02:00

Mislang AR, Wildes TM, Kanesvaran R, Baldini C, Holmes HM, Nightingale G, Coolbrandt A, Biganzoli L. Cancer Treat Rev. 2017 Jun;57:58-66. doi: 10.1016/j.ctrv.2017.05.002. Epub 2017 May 15.

Adherence to oral cancer therapy in older adults: The International Society of Geriatric Oncology (SIOG) taskforce recommendations2021-08-05T08:16:48+02:00

Frailty Research into the Medical Specialties-Report from a U13 Conference

2021-07-29T22:37:57+02:00

Walston J, Robinson TN, Zieman S, McFarland F, Carpenter CR, Althoff KN, Andrew MK, Blaum CS, Brown PJ, Buta B, Ely EW, Ferrucci L, High KP, Kritchevsky SB, Rockwood K, Schmader KE, Sierra F, Sink KM, Varadhan R, Hurria A. J Am Geriatr Soc. 2017 Apr 19. doi: 10.1111/jgs.14902. [Epub ahead of print] Integrating

Frailty Research into the Medical Specialties-Report from a U13 Conference2021-07-29T22:37:57+02:00

Assessment of the External Validity of the National Comprehensive Cancer Network and European Society for Medical Oncology Guidelines for Non-Small-Cell Lung Cancer in a Population of Patients Aged 80 Years and Older

2021-07-29T22:37:57+02:00

Battisti NML, Sehovic M, Extermann M. Clin Lung Cancer. 2017 Mar 21. pii: S1525-7304(17)30082-7. doi: 10.1016/j.cllc.2017.03.005. [Epub ahead of print]

Assessment of the External Validity of the National Comprehensive Cancer Network and European Society for Medical Oncology Guidelines for Non-Small-Cell Lung Cancer in a Population of Patients Aged 80 Years and Older2021-07-29T22:37:57+02:00

Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi

2021-07-29T22:37:57+02:00

Visco C, Chiappella A, Nassi L, Patti C, Ferrero S, Barbero D, Evangelista A, Spina M, Molinari A, Rigacci L, Tani M, Rocco AD, Pinotti G, Fabbri A, Zambello R, Finotto S, Gotti M, Carella AM, Salvi F, Pileri SA, Ladetto M, Ciccone G, Gaidano G, Ruggeri M, Martelli M, Vitolo U. Lancet Haematol. 2017 Jan;4(1):e15-e23. doi: 10.1016/S2352-3026(16)30185-5. Epub 2016 Dec 5.

Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi2021-07-29T22:37:57+02:00

Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial

2021-07-29T22:37:57+02:00

Kraeber-Bodere F, Pallardy A, Maisonneuve H, Campion L, Moreau A, Soubeyran I, Le Gouill S, Tournilhac O, Daguindau E, Jardel H, Morineau N, Bouabdallah K, Gyan E, Moles MP, Gressin R, Berthou C, Sadot S, Moreau P, Deau B, Bodet-Milin C, Cazeau AL, Garin E, Salaun PY, Vuillez JP, Gouilleux-Gruart V, Barbet J, Wegener WA, Goldenberg DM, Lamy T, Soubeyran P. Lancet Haematol. 2017 Jan;4(1):e35-e45. doi: 10.1016/S2352-3026(16)30168-5. Epub 2016 Dec 8.

Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial2021-07-29T22:37:57+02:00

Chirec Cancer Institute (CCI)

2025-06-12T19:29:22+02:00

Program Opportunities Involvement in any clinical activity: Clinical board and outpatient clinics; observership Availability of any funding supporting any trainee/researcher: Not available Duration of program: According to previous agreement, minimum 1 month Application process: Send a CV and letter of interest to the contact person Accepts international trainees: Yes Contact person: lissandra.dallago@chirec.be Website: https://www.chirec.be/fr/centre_parent/chirec-cancer-institute-cci  

Chirec Cancer Institute (CCI)2025-06-12T19:29:22+02:00

Radiopharmaceuticals in the elderly cancer patient: Practical considerations, with a focus on prostate cancer therapy: A position paper from the International Society of Geriatric Oncology Task Force

2021-07-29T22:37:57+02:00

John O. Prior, Silke Gillessen, Manfred Wirth, William Dale, Matti Aapro, Wim J.G. Oyen. European Journal of Cancer, Volume 77, May 2017

Radiopharmaceuticals in the elderly cancer patient: Practical considerations, with a focus on prostate cancer therapy: A position paper from the International Society of Geriatric Oncology Task Force2021-07-29T22:37:57+02:00

Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group

2021-07-29T22:37:57+02:00

Peyrade F, Bologna S, Delwail V, Emile JF, Pascal L, Fermé C, Schiano JM, Coiffier B, Corront B, Farhat H, Fruchart C, Ghesquieres H, Macro M, Tilly H, Choufi B, Delarue R, Fitoussi O, Gabarre J, Haioun C, Jardin F1 Lancet Haematol. 2017 Jan;4(1):e46-e55. doi: 10.1016/S2352-3026(16)30171-5.

Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group2021-07-29T22:37:57+02:00

Stay in touch and share our news!

SIOG Head Office

  • International Society of Geriatric Oncology
    P/A Comptabilis
    9 route des Jeunes
    1227 Les Acacias - Switzerland

  • +49 30 24603-152
  • enquiry@siog.org

ECOSOC Special

In Special Consultative Status with the United Nations Economic and Social Council (ECOSOC).

Quick links

 

Stay in the loop with SIOG’s newsletter!

Subscribe now

Powered by K.I.T. Group – Crafted for Excellence

Go to Top